Story
Founded in 2018, Koru Biotech began with a clear mission: to improve the detection of mastitis pathogens in dairy cows. Early development led to StaphGold, an ELISA-based laboratory test for detecting Staphylococcus aureus antibodies in milk. This work built deep capability in immunodiagnostics and field validation, while addressing a significant unmet need in dairy herd management.
During this research, a pivotal discovery emerged.
In studying mastitis biology more deeply, the team identified a novel lipopolysaccharide (LPS) immune complex biomarker with strong clinical relevance to Gram-negative infections. This discovery shifted the company’s trajectory from a single diagnostic product to a broader science-led platform opportunity.
Subsequent peer-reviewed publication validated the findings, demonstrating a clear correlation between elevated LPS immune complex levels and acute Gram-negative infection. With intellectual property secured, the company established a protected and scalable scientific foundation.
Today, Koru Biotech is pioneering an infection biology platform grounded in three core discoveries:
- A measurable biomarker linked to Gram-negative infections
- A targeted, non-antibiotic therapeutic strategy for Gram-negative pathogens
- A naturally occurring immune complex that helps protect newborns from disease
Together, these discoveries form the basis of a platform designed to detect, prevent, and manage infection with greater precision. We seek to reduce reliance on broad-spectrum antibiotics and to support a One Health approach across animal and human health.
Our journey reflects a simple belief: the future of infection control lies in better understanding the biological signals that drive disease.
What started in the dairy shed is now reshaping the future of bacterial diagnostics.
Building on this foundation, Koru is now developing breakthrough solutions for a wider range of bacterial diseases.